PE20121639A1 - Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40 - Google Patents

Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40

Info

Publication number
PE20121639A1
PE20121639A1 PE2012000884A PE2012000884A PE20121639A1 PE 20121639 A1 PE20121639 A1 PE 20121639A1 PE 2012000884 A PE2012000884 A PE 2012000884A PE 2012000884 A PE2012000884 A PE 2012000884A PE 20121639 A1 PE20121639 A1 PE 20121639A1
Authority
PE
Peru
Prior art keywords
alkyl
arylizothiazole
gpr40
hydroxy
halogen
Prior art date
Application number
PE2012000884A
Other languages
English (en)
Inventor
Akihiro Okano
Naoto Kosuga
Munetaka Ohkouchi
Daido Hotta
Muneyoshi Makabe
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of PE20121639A1 publication Critical patent/PE20121639A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UN DERIVADO DE 3-HIDROXI-5-ARILIZOTIAZOL DE FORMULA (I), DONDE n Y k SON UN ENTERO DE 0 A 2; p ES UN ENTERO DE 0 A 4; j ES UN ENTERO DE 0 A 3; EL ANILLO A ES UN GRUPO ARILO C6-C14 O UN HETEROCICLO DE 3 A 14 MIEMBROS, OPCIONALMENTE SUSTITUIDOS CON L; EL ANILLO B ES BENCENO, PIRIDINA O PIRIMIDINA; X ES O, S, NR7; R1 ES HALOGENO, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R2 ES H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; R3, R4, R5, R6 Y R7 SON H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; L ES HALOGENO, OH, CN, ALQUILO C1-C10, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS MODULAN LA FUNCION DEL RECEPTOR 40 ACOPLADO A LA PROTEINA G (GPR40) Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS TALES COMO LA DIABETES
PE2012000884A 2009-12-25 2010-12-24 Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40 PE20121639A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009295855 2009-12-25
JP2010043420 2010-02-26

Publications (1)

Publication Number Publication Date
PE20121639A1 true PE20121639A1 (es) 2012-12-02

Family

ID=44195895

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000884A PE20121639A1 (es) 2009-12-25 2010-12-24 Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40

Country Status (25)

Country Link
US (1) US8476287B2 (es)
EP (1) EP2518060A4 (es)
JP (2) JP5002077B2 (es)
KR (1) KR20130004262A (es)
CN (2) CN104710381A (es)
AU (1) AU2010336225A1 (es)
BR (1) BR112012015612A2 (es)
CA (1) CA2785674A1 (es)
CL (1) CL2012001722A1 (es)
CO (1) CO6650337A2 (es)
CR (1) CR20120345A (es)
EA (1) EA201290574A1 (es)
EC (1) ECSP12012056A (es)
GT (1) GT201200217A (es)
HN (1) HN2012001351A (es)
IL (1) IL220616A0 (es)
MA (1) MA33952B1 (es)
MX (1) MX2012007474A (es)
NI (1) NI201200113A (es)
NZ (1) NZ601408A (es)
PE (1) PE20121639A1 (es)
RU (1) RU2567755C2 (es)
SG (1) SG181961A1 (es)
WO (1) WO2011078371A1 (es)
ZA (1) ZA201203416B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2779398A1 (en) 2009-10-30 2011-05-05 Mochida Phamaceutical Co., Ltd. Novel 3-hydroxy-5-arylisoxazole derivative
PE20121639A1 (es) 2009-12-25 2012-12-02 Mochida Pharm Co Ltd Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40
US8581584B2 (en) * 2010-05-26 2013-11-12 Florida State University Research Foundation Membrane proteins, mechanisms of action and uses thereof
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
BR122021002201A8 (pt) 2011-02-25 2023-04-11 Merck Sharp & Dohme Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
TW201247636A (en) 2011-04-27 2012-12-01 Mochida Pharm Co Ltd Novel 3-hydroxyisothiazole 1-oxide derivatives
CA2834465A1 (en) * 2011-04-28 2012-11-01 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2013154163A1 (ja) * 2012-04-11 2013-10-17 持田製薬株式会社 新規５－アリール－１，２－チアジナン誘導体
KR102089239B1 (ko) 2012-04-24 2020-03-16 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
KR20150036245A (ko) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 항당뇨병 트리시클릭 화합물
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
ES2900061T3 (es) 2013-03-12 2022-03-15 Vertex Pharma Inhibidores de DNA-PK
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP6408569B2 (ja) 2013-10-17 2018-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
WO2015097713A1 (en) 2013-11-14 2015-07-02 Cadila Healthcare Limited Novel heterocyclic compounds
CA2977764C (en) * 2015-02-27 2021-11-09 Nantbioscience, Inc. Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
TW201815418A (zh) 2016-09-27 2018-05-01 Vertex Pharma 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
KR102586510B1 (ko) 2018-02-13 2023-10-12 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
CN110066254B (zh) * 2018-11-16 2021-03-19 温州大学 一种异噻唑-3-酮化合物的制备方法
AU2020363377A1 (en) 2019-10-07 2022-04-21 Kallyope, Inc. GPR119 agonists
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN115433143B (zh) * 2021-06-03 2023-10-13 中国科学院大连化学物理研究所 一种异噻唑啉酮类化合物的合成方法
CN115386028B (zh) * 2022-08-26 2023-06-23 长春理工大学 一种聚合度可控的聚山梨酸-d-薄荷醇酯及合成方法与应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562283A (en) 1968-07-01 1971-02-09 Rohm & Haas 1-oxo and 1,1-dioxo-3-isothiazolones
US3801575A (en) 1972-01-24 1974-04-02 Rohm & Haas 3-hydroxyisothiazoles
EP0885891A4 (en) 1996-02-27 2001-02-21 Sankyo Co ISOXAZOLE DERIVATIVES
DE69926914T2 (de) 1999-01-13 2006-06-29 Warner-Lambert Co. Llc 1-heterozyklus-substituierte diarylaminen
JP2000204077A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
WO2004011446A1 (en) 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
AU2003261935A1 (en) 2002-09-06 2004-03-29 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
US20080009530A1 (en) 2005-08-10 2008-01-10 Hidenori Abe Therapeutic Agent for Diabetes
AU2006291234A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
AR061644A1 (es) 2006-06-27 2008-09-10 Takeda Pharmaceutical Derivados de benzofurano
WO2008030520A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Heterocyclic gpr40 modulators
WO2008033931A1 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib
US8367708B2 (en) 2006-12-01 2013-02-05 Msd K.K. Phenyl-isoxazol-3-ol derivative
JP2010524932A (ja) 2007-04-16 2010-07-22 アムジエン・インコーポレーテツド 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸ｇｐｒ４０調節物質
KR20100061692A (ko) 2007-09-21 2010-06-08 사노피-아벤티스 （카복실알킬렌-페닐）-페닐-옥살아미드, 이의 제조 방법 및 의약으로서의 이의 용도
WO2009048527A1 (en) 2007-10-10 2009-04-16 Amgen Inc. Substituted biphenyl gpr40 modulators
JP2011016722A (ja) 2007-10-23 2011-01-27 Astellas Pharma Inc チアゾリジンジオン化合物
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
BRPI0818687A2 (pt) 2007-10-26 2017-05-02 Japan Tobacco Inc composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
JP2011515341A (ja) 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
JPWO2009147990A1 (ja) * 2008-06-02 2011-10-27 Ｍｓｄ株式会社 新規イソオキサゾール誘導体
KR20110027657A (ko) 2008-06-25 2011-03-16 다이이찌 산쿄 가부시키가이샤 카르복실산 화합물
JP2012515781A (ja) 2009-01-23 2012-07-12 シェーリング コーポレイション 架橋および縮合複素環式抗糖尿病化合物
WO2010091176A1 (en) 2009-02-05 2010-08-12 Schering Corporation Phthalazine-containing antidiabetic compounds
EP2440541A1 (en) 2009-06-09 2012-04-18 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
CA2779398A1 (en) 2009-10-30 2011-05-05 Mochida Phamaceutical Co., Ltd. Novel 3-hydroxy-5-arylisoxazole derivative
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
PE20121639A1 (es) 2009-12-25 2012-12-02 Mochida Pharm Co Ltd Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40
CN101781268B (zh) 2010-02-25 2012-05-30 中国人民解放军军事医学科学院毒物药物研究所 异噻唑酮取代的苯二羧酸衍生物及其用于制备β-分泌酶抑制剂的用途
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体

Also Published As

Publication number Publication date
HN2012001351A (es) 2015-03-23
KR20130004262A (ko) 2013-01-09
JP2012153726A (ja) 2012-08-16
CN104710381A (zh) 2015-06-17
RU2567755C2 (ru) 2015-11-10
MA33952B1 (fr) 2013-01-02
AU2010336225A1 (en) 2012-08-16
ZA201203416B (en) 2013-08-28
MX2012007474A (es) 2012-08-01
US8476287B2 (en) 2013-07-02
ECSP12012056A (es) 2012-10-30
CN102712610B (zh) 2015-03-04
CN102712610A (zh) 2012-10-03
IL220616A0 (en) 2012-08-30
RU2012131840A (ru) 2014-01-27
GT201200217A (es) 2014-02-10
US20120157459A1 (en) 2012-06-21
WO2011078371A1 (ja) 2011-06-30
BR112012015612A2 (pt) 2016-03-15
CR20120345A (es) 2012-11-01
JP5002077B2 (ja) 2012-08-15
NZ601408A (en) 2013-12-20
SG181961A1 (en) 2012-08-30
CA2785674A1 (en) 2011-06-30
JPWO2011078371A1 (ja) 2013-05-09
EP2518060A4 (en) 2014-01-08
CL2012001722A1 (es) 2012-12-14
NI201200113A (es) 2012-08-13
EP2518060A1 (en) 2012-10-31
CO6650337A2 (es) 2013-04-15
EA201290574A1 (ru) 2012-12-28

Similar Documents

Publication Publication Date Title
PE20121639A1 (es) Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40
PE20191495A1 (es) Piridonamidas como moduladores de canales de sodio
EA201390947A1 (ru) Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
CY1114718T1 (el) ΠΑΡΑΓΩΓΑ 1,2,4-ΤΡΙΑΖΟΛΟ[4,3-a]ΠΥΡΙΔΙΝΗΣ ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ Ή ΤΗΝ ΠΡΟΛΗΨΗ ΝΕΥΡΟΛΟΓΙΚΩΝ ΚΑΙ ΨΥΧΙΑΤΡΙΚΩΝ ΔΙΑΤΑΡΑΧΩΝ
EA201290774A1 (ru) Пиразолопиридиновые, пиразолопиразиновые, пиразолопиримидиновые, пиразолотиофеновые и пиразолотиазоловые соединения как аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
DOP2013000181A (es) Moduladores del receptor de glucagon
EA200971143A1 (ru) Бензамидные mglur5 позитивные аллостерические модуляторы и способы их получения и применения
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
EA200870196A1 (ru) Индолсульфонамидные модуляторы рецепторов прогестерона
UY32888A (es) Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparación y uso de las mismas
MX2011005242A (es) Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
PE20090158A1 (es) Dihidro y tetrahidro oxazolopirimidinonas sustituidas y preparaciones de las mismas
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
EA200870197A1 (ru) Новые 2-замещённые бензимидазолы в качестве селективных модуляторов рецептора андрогена (sarms)
EA201190138A1 (ru) Производные фуропиримидиндиона в качестве модуляторов trpa1
PE20120561A1 (es) Compuestos que modulan selectivamente el receptor cb2
PE20141211A1 (es) Moduladores receptores de hormonas nucleares
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
PE20160589A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas de los receptores de vasopresina v1a
PE20130401A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos
PE20141556A1 (es) Derivados de etinilo como moduladores alostericos de mglur5
CL2009000116A1 (es) Compuestos derivados de heterotriciclos sustituidos, antagonistas del receptor crf; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento de trastornos afectivos, depresion, ansiedad y sindrome del colon irritable.
CO6321281A2 (es) Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs)
CO6541592A2 (es) Tiazoles biciclicos como moduladores alostericos de receptores de mglur5
CY1119449T1 (el) Ενωσεις 1,2,4-τριαζολο|4,3-α]πυριδινης και η χρηση αυτων ως θετικων αλλοστερiκων ρυθμιστων των υποδοχεων mglur2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal